Related Experiment Videos
Anti-antibody enhancement of tumor imaging
Cancer Treatment and Research
|January 1, 1990
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2021
Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
Annals of oncology : official journal of the European Society for Medical Oncology·2020
Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
European journal of nuclear medicine and molecular imaging·2020
Immunization with HIV-1 envelope T20-encoding DNA vaccines elicits cross-clade neutralizing antibody responses.
Human vaccines & immunotherapeutics·2017
Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.
Bioconjugate chemistry·2014
Clinical Trials and Translational Advances in Metabolic Targeting.
Cancer treatment and research·2026
Tools and Technologies for Studying Cancer Metabolism.
Cancer treatment and research·2026
Cancer and Immune Cells: A Metabolic Battle in the Tumor Microenvironment.
Cancer treatment and research·2026
Biomarkers of Cancer Metabolism and Therapeutic Response.
Cancer treatment and research·2026
Targeting Metabolism in Cancer Therapy: Inhibitors and Approaches.
Cancer treatment and research·2026
Metabolic Reprogramming in Cancer Stem Cells.
Cancer treatment and research·2026
Spatial statistics infer structured immune signatures in primary prostate cancer.
Cancer immunology research·2026
Integrated molecular and immune profiling identifies FOXA1 as a complementary co-target to MUC1 for bispecific immunotherapy in breast cancer.
Functional & integrative genomics·2026
Incidental Thyroid Uptake on 18F-FES PET/CT Revealing Papillary Thyroid Carcinoma.
Clinical nuclear medicine·2026
IL-23 promotes PD-L1 expression and tumor immune evasion via METTL16 pathway.
American journal of cancer research·2026